<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinform Adv</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinform Adv</journal-id>
    <journal-id journal-id-type="publisher-id">bioadv</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics Advances</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2635-0041</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8600631</article-id>
    <article-id pub-id-type="pmid">34806017</article-id>
    <article-id pub-id-type="doi">10.1093/bioadv/vbab021</article-id>
    <article-id pub-id-type="publisher-id">vbab021</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Article</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>CRIS: complete reconstruction of immunoglobulin <italic toggle="yes">V-D-J</italic> sequences from RNA-seq data</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6747-6191</contrib-id>
        <name>
          <surname>Islam</surname>
          <given-names>Rashedul</given-names>
        </name>
        <xref rid="vbab021-aff1" ref-type="aff">1</xref>
        <xref rid="vbab021-aff2" ref-type="aff">2</xref>
        <xref rid="vbab021-aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bilenky</surname>
          <given-names>Misha</given-names>
        </name>
        <xref rid="vbab021-aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Weng</surname>
          <given-names>Andrew P</given-names>
        </name>
        <xref rid="vbab021-aff4" ref-type="aff">4</xref>
        <xref rid="vbab021-aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1361-7531</contrib-id>
        <name>
          <surname>Connors</surname>
          <given-names>Joseph M</given-names>
        </name>
        <xref rid="vbab021-aff6" ref-type="aff">6</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Hirst</surname>
          <given-names>Martin</given-names>
        </name>
        <xref rid="vbab021-aff1" ref-type="aff">1</xref>
        <xref rid="vbab021-aff2" ref-type="aff">2</xref>
        <xref rid="vbab021-aff3" ref-type="aff">3</xref>
        <xref rid="vbab021-cor1" ref-type="corresp"/>
        <!--mhirst@bcgsc.ca-->
      </contrib>
    </contrib-group>
    <aff id="vbab021-aff1"><label>1</label><institution>Bioinformatics Graduate Program, University of British Columbia</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
    <aff id="vbab021-aff2"><label>2</label><institution>Department of Microbiology and Immunology, Michael Smith Laboratories, University of British Columbia</institution>, Vancouver, BC V6T 1Z3, <country country="CA">Canada</country></aff>
    <aff id="vbab021-aff3"><label>3</label><institution>Canada’s Michael Smith Genome Sciences Centre, BC Cancer</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
    <aff id="vbab021-aff4"><label>4</label><institution>Terry Fox Laboratory, BC Cancer</institution>, Vancouver, BC V5Z 1L3, <country country="CA">Canada</country></aff>
    <aff id="vbab021-aff5"><label>5</label><institution>Department of Pathology &amp; Laboratory Medicine, University of British Columbia</institution>, Vancouver, BC V6T 2B5, <country country="CA">Canada</country></aff>
    <aff id="vbab021-aff6"><label>6</label><institution>Department of Medical Oncology, BC Cancer</institution>, Vancouver, BC, V5Z 4E6, <country country="CA">Canada</country></aff>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Ouangraoua</surname>
          <given-names>Aida</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="vbab021-cor1">To whom correspondence should be addressed. <email>mhirst@bcgsc.ca</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2021-09-09">
      <day>09</day>
      <month>9</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>09</day>
      <month>9</month>
      <year>2021</year>
    </pub-date>
    <volume>1</volume>
    <issue>1</issue>
    <elocation-id>vbab021</elocation-id>
    <history>
      <date date-type="received">
        <day>16</day>
        <month>6</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>08</day>
        <month>8</month>
        <year>2021</year>
      </date>
      <date date-type="editorial-decision">
        <day>31</day>
        <month>8</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>06</day>
        <month>9</month>
        <year>2021</year>
      </date>
      <date date-type="corrected-typeset">
        <day>18</day>
        <month>11</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2021. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="vbab021.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>B cells display remarkable diversity in producing B-cell receptors through recombination of immunoglobulin (Ig) <italic toggle="yes">V-D-J</italic> genes. Somatic hypermutation (SHM) of immunoglobulin heavy chain variable (<italic toggle="yes">IGHV</italic>) genes are used as a prognostic marker in B-cell malignancies. Clinically, <italic toggle="yes">IGHV</italic> mutation status is determined by targeted Sanger sequencing which is a resource-intensive and low-throughput procedure. Here, we describe a bioinformatic pipeline, CRIS (Complete Reconstruction of Immunoglobulin <italic toggle="yes">IGHV-D-J</italic> Sequences) that uses RNA sequencing (RNA-seq) datasets to reconstruct <italic toggle="yes">IGHV-D-J</italic> sequences and determine <italic toggle="yes">IGHV</italic> SHM status.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>CRIS extracts RNA-seq reads aligned to Ig gene loci, performs assembly of Ig transcripts and aligns the resulting contigs to reference Ig sequences to enumerate and classify SHMs in the <italic toggle="yes">IGHV</italic> gene sequence. CRIS improves on existing tools that infer the B-cell receptor repertoire from RNA-seq data using a portion <italic toggle="yes">IGHV</italic> gene segment by <italic toggle="yes">de novo</italic> assembly. We show that the SHM status identified by CRIS using the entire <italic toggle="yes">IGHV</italic> gene segment is highly concordant with clinical classification in three independent chronic lymphocytic leukemia patient cohorts.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>The CRIS pipeline is available under the MIT License from <ext-link xlink:href="https://github.com/Rashedul/CRIS" ext-link-type="uri">https://github.com/Rashedul/CRIS</ext-link>.</p>
      </sec>
      <sec id="s4">
        <title>Supplementary information</title>
        <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics Advances</italic> online.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Canadian Institutes of Health Research</institution>
            <institution-id institution-id-type="DOI">10.13039/501100000024</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>EP1-120589</award-id>
        <award-id>CEE-151619</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Genome Canada (C41EMT and C32EMT) under the Canadian Epigenetics, Environment and Health Research Consortium (to M.H.</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Terry Fox Research Institute Program Projects</institution>
          </institution-wrap>
        </funding-source>
        <award-id>TFF‐122869 and TFRI-1074</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>CIHR Bioinformatics Training Program for Health Research</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>University of British Columbia, Vancouver, BC, Canada</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="7"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>During development in the bone marrow, B lymphocytes undergo rearrangement of immunoglobulin (Ig) heavy (V, D and J) and light chain (V and J) gene segments through recombination (<xref rid="vbab021-F1" ref-type="fig">Fig. 1</xref>). Addition or deletion of nucleotides occurs at segment junctions during recombination. In the germinal center, B-cells acquire additional somatic hypermutation (SHM) within the Ig variable regions as part of the adaptive immune response to generate a B-cell receptor (BCR) repertoire diversity estimated to be as much as ∼10<sup>18</sup> (<xref rid="vbab021-B8" ref-type="bibr">Briney <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="vbab021-B19" ref-type="bibr">Janeway <italic toggle="yes">et al.</italic>, 2004</xref>). Following SHM, B cells are positively selected for further differentiation into memory B cells or antibody-secreting plasma cells (<xref rid="vbab021-B1" ref-type="bibr">Akkaya <italic toggle="yes">et al.</italic>, 2020</xref>).</p>
    <fig position="float" id="vbab021-F1">
      <label>Fig. 1.</label>
      <caption>
        <p><italic toggle="yes">IGHV-D-J</italic> recombination and SHM during B-cell development. BCRs are generated by ordered assembly of the Ig heavy chain gene segments (<italic toggle="yes">V</italic>, <italic toggle="yes">D</italic> and <italic toggle="yes">J</italic>) during B-cell development. Addition and deletion of junctional nucleotides (N) contribute to the diversity of BCR repertoires. BCR sequences undergo affinity maturation upon antigen stimulation through SHMs in the variable domain (indicated in black arrows). SHMs of Ig are enriched at the complementarity-determining regions (CDRs)</p>
      </caption>
      <graphic xlink:href="vbab021f1" position="float"/>
    </fig>
    <p>Profiling of the B-cell Ig repertoire has become an essential component of immune research and is used clinically for malignant B-cell classification (<xref rid="vbab021-B8" ref-type="bibr">Briney <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="vbab021-B12" ref-type="bibr">Georgiou <italic toggle="yes">et al.</italic>, 2014</xref>). B-cell malignancies arise at different stages of B-cell development and BCR diversification is used as both a prognostic and diagnostic marker (<xref rid="vbab021-B12" ref-type="bibr">Georgiou <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="vbab021-B24" ref-type="bibr">Monk <italic toggle="yes">et al.</italic>, 2017</xref>). The presence of SHM and specific usage of immunoglobulin heavy chain variable (<italic toggle="yes">IGHV</italic>) genes are prognostic markers in different B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and follicular lymphoma (<xref rid="vbab021-B4" ref-type="bibr">Berget <italic toggle="yes">et al.</italic>, 2015</xref>; <xref rid="vbab021-B10" ref-type="bibr">Damle <italic toggle="yes">et al.</italic>, 1999</xref>; <xref rid="vbab021-B15" ref-type="bibr">Hamblin <italic toggle="yes">et al.</italic>, 1999</xref>; <xref rid="vbab021-B26" ref-type="bibr">Navarro <italic toggle="yes">et al.</italic>, 2012</xref>). Malignant B cells are classified into two major subtypes based on the SHM status, where cells with very low SHM are classified as ‘unmutated <italic toggle="yes">IGHV</italic>’ subtype, while those cells with evidence of SHM are classified as ‘mutated <italic toggle="yes">IGHV</italic>’ subtype. Unmutated <italic toggle="yes">IGHV</italic> subtypes of CLL and MCL show more aggressive disease compared to the mutated <italic toggle="yes">IGHV</italic> subtype (<xref rid="vbab021-B10" ref-type="bibr">Damle <italic toggle="yes">et al.</italic>, 1999</xref>; <xref rid="vbab021-B15" ref-type="bibr">Hamblin <italic toggle="yes">et al.</italic>, 1999</xref>; <xref rid="vbab021-B26" ref-type="bibr">Navarro <italic toggle="yes">et al.</italic>, 2012</xref>). <italic toggle="yes">IGHV</italic> gene usage is also used as a prognostic in follicular lymphoma (<xref rid="vbab021-B4" ref-type="bibr">Berget <italic toggle="yes">et al.</italic>, 2015</xref>).</p>
    <p>SHM analysis of the <italic toggle="yes">IGHV</italic> gene is commonly performed using multiplex PCR and Sanger sequencing following the best practice guidelines by the European Research Initiative on CLL (ERIC) (<xref rid="vbab021-B13" ref-type="bibr">Ghia <italic toggle="yes">et al.</italic>, 2007</xref>). However the PCR-Sanger method is resource-intensive and technically challenging in both clinical and research applications and suffers from a 9% to 18% failure rate (<xref rid="vbab021-B30" ref-type="bibr">Stamatopoulos <italic toggle="yes">et al.</italic>, 2017</xref>). Massively parallel sequencing of targeted genomic DNA regions or RNA has emerged as an alternative method to reliably sequence <italic toggle="yes">V-D-J</italic> segments (<xref rid="vbab021-B7" ref-type="bibr">Boyd and Joshi, 2014</xref>; <xref rid="vbab021-B12" ref-type="bibr">Georgiou <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="vbab021-B23" ref-type="bibr">Menzel <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="vbab021-B33" ref-type="bibr">Yaari and Kleinstein, 2015</xref>). RNA sequencing (RNA-seq) has become the gold standard for transcriptome analysis, applied in both clinical and research settings and has been used in limited cases to identify BCR rearrangement repertoire (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic>, 2015</xref>; <xref rid="vbab021-B18" ref-type="bibr">Iglesia <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="vbab021-B24" ref-type="bibr">Monk <italic toggle="yes">et al.</italic>, 2017</xref>; <xref rid="vbab021-B25" ref-type="bibr">Mose <italic toggle="yes">et al.</italic>, 2016</xref>).</p>
    <p>Several bioinformatic pipelines have been developed to infer BCR repertoire from RNA-seq data, including ABRA (<xref rid="vbab021-B18" ref-type="bibr">Iglesia <italic toggle="yes">et al.</italic>, 2014</xref>), TRUST (<xref rid="vbab021-B17" ref-type="bibr">Hu <italic toggle="yes">et al.</italic>, 2019</xref>), ImReP (<xref rid="vbab021-B21" ref-type="bibr">Mandric <italic toggle="yes">et al.</italic>, 2020</xref>), MiXCR (<xref rid="vbab021-B6" ref-type="bibr">Bolotin <italic toggle="yes">et al.</italic>, 2015</xref>), V’DJer (<xref rid="vbab021-B25" ref-type="bibr">Mose <italic toggle="yes">et al.</italic>, 2016</xref>) and IgID (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic>, 2015</xref>). Among them, ABRA (<xref rid="vbab021-B18" ref-type="bibr">Iglesia <italic toggle="yes">et al.</italic>, 2014</xref>) and IgID (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic>, 2015</xref>) were not published with stand-alone code to allow for replication. The remaining <italic toggle="yes">IGHV-D-J</italic> reconstruction tools (e.g. TRUST, ImReP, MiXCR and V'DJer) were designed to reconstruct only the CDR3 region, representing only a portion of the <italic toggle="yes">IGHV</italic> gene, while the entire <italic toggle="yes">IGHV</italic> gene segment is required to determine the SHM status in B-cell malignancies. In addition, these tools have not been validated against gold standard PCR-Sanger datasets for SHM classification. To address these gaps in determining <italic toggle="yes">IGHV</italic> mutational status in B-cell malignancies, we developed a bioinformatic pipeline, CRIS (Complete Reconstruction of Immunoglobulin <italic toggle="yes">IGHV-D-J</italic> Sequences), which extracts RNA-seq reads aligned to putative Ig loci, assembles the complete <italic toggle="yes">IGHV</italic> gene, identifies the most abundant Ig transcript and enumerates SHMs by comparison with germline reference sequences. Classification of <italic toggle="yes">IGHV</italic> mutational subtypes by CRIS was validated against PCR-Sanger-based clinical classification in three independent cohorts of CLL patients and shown to be comparable.</p>
  </sec>
  <sec>
    <title>2 Methods</title>
    <sec>
      <title>2.1 CLL samples</title>
      <p>In the Centre for Epigenomic Technology (CEMT) cohort, peripheral blood samples were obtained from CLL patients undergoing treatment at BC Cancer (<italic toggle="yes">n</italic> = 16) and used according to procedures approved by the Research Ethics Board (REB H12-01767) of the University of British Columbia (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). RNA was purified from those peripheral blood samples and extraction was performed on CD19+ sorted cells with &gt;90% purity as described (<xref rid="vbab021-B28" ref-type="bibr">Pellacani <italic toggle="yes">et al.</italic>, 2016</xref>).</p>
    </sec>
    <sec>
      <title>2.2 RNA sequencing</title>
      <p>The CEMT CLL RNA-seq datasets were generated as described (<xref rid="vbab021-B28" ref-type="bibr">Pellacani <italic toggle="yes">et al.</italic>, 2016</xref>). RNA extraction, library construction and sequencing were performed following the guidelines formulated by the International Human Epigenome Consortium (<ext-link xlink:href="http://www.ihec-epigenomes.org" ext-link-type="uri">http://www.ihec-epigenomes.org</ext-link>). These guidelines as well as the standard operating procedures for RNA-seq library construction and sequencing are available at <ext-link xlink:href="https://thisisepigenetics.ca/for-scientists/protocols-and-standards" ext-link-type="uri">https://thisisepigenetics.ca/for-scientists/protocols-and-standards</ext-link> and by request. Additional CLL patient RNA-seq datasets with matching <italic toggle="yes">IGHV</italic> mutation status were collected from published datasets: GSE66228 (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic>, 2015</xref>), EGAD00001004046 (<xref rid="vbab021-B3" ref-type="bibr">Beekman <italic toggle="yes">et al.</italic>, 2018</xref>) and phs000435.v3 (<xref rid="vbab021-B32" ref-type="bibr">Wang <italic toggle="yes">et al.</italic>, 2011</xref>).</p>
    </sec>
    <sec>
      <title>2.3 Identification of putative Ig loci</title>
      <p>We identified five putative Ig loci enriched with reads that were used to reconstruct Ig containing contigs in the 16 CEMT samples (<xref rid="vbab021-T1" ref-type="table">Table 1</xref>). The detailed procedure of identifying Ig loci is described in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1a</xref>.</p>
      <table-wrap position="float" id="vbab021-T1">
        <label>Table 1.</label>
        <caption>
          <p>Genomic coordinates of the putative Ig loci in the GRCh38 reference</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="center" span="1"/>
            <col valign="top" align="center" span="1"/>
            <col valign="top" align="center" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Chromosome/contig</th>
              <th rowspan="1" colspan="1">Start</th>
              <th rowspan="1" colspan="1">End</th>
              <th rowspan="1" colspan="1">Length (bp)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Chr14</td>
              <td rowspan="1" colspan="1">105 550 001</td>
              <td rowspan="1" colspan="1">106 880 000</td>
              <td rowspan="1" colspan="1">1 329 999</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Chr15</td>
              <td rowspan="1" colspan="1">21 710 000</td>
              <td rowspan="1" colspan="1">22 190 000</td>
              <td rowspan="1" colspan="1">480 000</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Chr16</td>
              <td rowspan="1" colspan="1">31 950 001</td>
              <td rowspan="1" colspan="1">33 970 000</td>
              <td rowspan="1" colspan="1">2 019 999</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">chr14_KI270726v1_random</td>
              <td rowspan="1" colspan="1">1</td>
              <td rowspan="1" colspan="1">43 739</td>
              <td rowspan="1" colspan="1">43 739</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">chr16_KI270728v1_random</td>
              <td rowspan="1" colspan="1">1</td>
              <td rowspan="1" colspan="1">1 872 759</td>
              <td rowspan="1" colspan="1">1 872 759</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec>
      <title>2.4 CRIS pipeline</title>
      <list list-type="bullet">
        <list-item>
          <p><bold>Step 1:</bold><italic toggle="yes">Read extraction prior to assembly of Ig</italic><italic toggle="yes">transcripts:</italic> hg38-bam-file was created by aligning the reads to the GRCh38 reference genome using BWA mem (v0.7.6a; <xref rid="vbab021-B20" ref-type="bibr">Li and Durbin, 2009</xref>). Using sambamba (v0.7.0; <xref rid="vbab021-B31" ref-type="bibr">Tarasov <italic toggle="yes">et al.</italic>, 2015</xref>), we extracted reads that were aligned to the putative <italic toggle="yes">IGHV</italic> loci (<xref rid="vbab021-T1" ref-type="table"><bold>Table 1</bold></xref>) and saved them in fastq format using Picard SamToFastq (v2.20.3; <xref rid="vbab021-B9" ref-type="bibr">Broad Institute, 2009</xref>; <xref rid="vbab021-F2" ref-type="fig"><bold>Fig. 2</bold></xref>). These resultant paired-end reads originated from the putative Ig loci were used as input for Trinity (v2.1.1; <xref rid="vbab021-B14" ref-type="bibr">Grabherr <italic toggle="yes">et al.</italic>, 2011</xref>) for <italic toggle="yes">de novo</italic> transcriptome assembly.</p>
        </list-item>
        <list-item>
          <p><bold>Step 2:</bold><italic toggle="yes">Identification of Ig</italic><italic toggle="yes">transcripts and their abundances:</italic> Trinity assembly performed in the previous step produced around 250 transcripts per sample. To filter the transcripts that have similarity (expectation value ≤20) with the germline <italic toggle="yes">IGHV</italic> sequences, we used blastn (v2.9.0; <xref rid="vbab021-B2" ref-type="bibr">Altschul <italic toggle="yes">et al.</italic>, 1990</xref>) with default parameters with a custom database of <italic toggle="yes">IGHV</italic> sequences downloaded from the international ImMunoGeneTics information system (IMGT) (<xref rid="vbab021-B29" ref-type="bibr">Giudicelli <italic toggle="yes">et al.</italic>, 2005</xref>). The resultant Ig transcripts were used in Salmon (v0.8.1; <xref rid="vbab021-B27" ref-type="bibr">Patro <italic toggle="yes">et al.</italic>, 2017</xref>) to quantify their abundances with a k-mer of 31 bp. Transcript with the highest TPM (transcripts per million) value was marked as the dominant clone.</p>
        </list-item>
        <list-item>
          <p><bold>Step 3:</bold><italic toggle="yes">SHM and clonotype analysis:</italic> The Ig-transcript sequences identified in step 2 were queried in IgBLAST (v1.14.0; <xref rid="vbab021-B34" ref-type="bibr">Ye <italic toggle="yes">et al.</italic>, 2013</xref>) against the germline <italic toggle="yes">V</italic>, <italic toggle="yes">D and J</italic> gene database of IMGT. IgBLAST returned the percent identity of the <italic toggle="yes">IGHV</italic> segment of Ig transcripts compared to the germline alleles and clustered the similar Ig transcripts into clonotypes. Productive Ig transcript with highest TPM value was used to determine <italic toggle="yes">IGHV</italic> mutation status of CLL sample and further compared with available clinical PCR-Sanger data. Transcripts having TPM values within one log10 of the highest expressed transcript were also considered while comparing with the PCR-Sanger data according to (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic> 2015</xref>).</p>
        </list-item>
      </list>
      <fig position="float" id="vbab021-F2">
        <label>Fig. 2.</label>
        <caption>
          <p>CRIS workflow. CRIS extract reads from the putative Ig loci prior to assembly of Ig transcripts and quantify transcript abundances. The percent of <italic toggle="yes">IGHV</italic> mutations of Ig transcripts is calculated by comparing to the germline sequences</p>
        </caption>
        <graphic xlink:href="vbab021f2" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>2.5 Analysis of SHM status using V’DJer, TRUST and MiXCR</title>
      <p>V’DJer, TRUST (v3.0.3) and MiXCR (v3.0.3) were run on the RNA-seq bam file generated by STAR (v2.7.5a) aligner (<xref rid="vbab021-B11" ref-type="bibr">Dobin <italic toggle="yes">et al.</italic>, 2013</xref>) using GRCh38 genome as reference. During STAR alignment ‘–outSAMunmapped Within’ was used to include the unmapped reads in the bam file. All three tools were run with default parameters to generate VDJ contigs of IGH. VDJ contigs were analyzed by IgBLAST to generate the percent identity of <italic toggle="yes">IGHV</italic> sequences compared to the germline database.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <sec>
      <title>3.1 <italic toggle="yes">De novo</italic> assembly-based Ig detection from RNA-seq</title>
      <p><italic toggle="yes">De novo</italic> assembly using Trinity (<xref rid="vbab021-B14" ref-type="bibr">Grabherr <italic toggle="yes">et al.</italic>, 2011</xref>) for 16 deeply sequenced (∼300 M read pairs) CLL RNA-seq libraries generated an average of ∼450 000 contigs per sample with 6–29 contigs demonstrating <italic toggle="yes">IGHV</italic> sequence homology. However, <italic toggle="yes">de novo</italic> assembly of the complete RNA-seq read sets required significant computational resources (<xref rid="vbab021-B16" ref-type="bibr">Hölzer and Marz, 2019</xref>) and thus we sought to identify the fraction of reads in the RNA-seq libraries corresponding to the Ig loci. Using the resulting assemblies, we found that on average 99.85% of the sequence reads used to reconstruct <italic toggle="yes">IGHV</italic> containing contigs originated from five putative Ig loci in the GRCh38 reference (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). These putative Ig loci consist of human Ig locus, Ig pseudogene loci and unlocalized contigs at chromosomes 14, 15 and 16 (<xref rid="vbab021-T1" ref-type="table">Table 1</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2</xref>). This suggests that sequence reads used to reconstruct Ig sequence not only map to the reference Ig locus but also to pseudogene regions both within the current assembly and in unlocalized contigs. We hypothesized that this novel set of loci could be used as a highly specific filter to reconstruct <italic toggle="yes">IGHV-D-J</italic> sequence.</p>
    </sec>
    <sec>
      <title>3.2 CRIS pipeline development</title>
      <p>Given the time required to complete a full assembly from an RNA-seq library, we sought to extract Ig sequences prior to performing assembly. For this, we leveraged the putative Ig loci identified in our pilot set of libraries, retrieved sequences aligned by BWA mem (<xref rid="vbab021-B20" ref-type="bibr">Li and Durbin, 2009</xref>) within these coordinates (∼1% of all reads) and subjected these to <italic toggle="yes">de novo</italic> assembly using Trinity (<xref rid="vbab021-B14" ref-type="bibr">Grabherr <italic toggle="yes">et al.</italic>, 2011</xref>). Enriching for Ig sequences from the bulk RNA-seq sequence set reduced the run time for assembly by two orders of magnitude while not significantly impacting the subsequent SHM analysis of Ig transcripts (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). We confirmed that our approach also successfully assembled the <italic toggle="yes">IGHV-D-J</italic> and N-junctional segments (<xref rid="vbab021-F3" ref-type="fig">Fig. 3a</xref>, <xref rid="vbab021-T2" ref-type="table">Table 2</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>).</p>
      <fig position="float" id="vbab021-F3">
        <label>Fig. 3.</label>
        <caption>
          <p>Evaluation of CRIS to reconstruct <italic toggle="yes">IGHV-D-J</italic> sequences. (<bold>a</bold>) The most abundant Ig transcript from US-1422278 sample was aligned to the germline database using IgBLAST where top hit germline genes are shown. In the alignment, mismatches are represented as nucleotide bases and matches as dots. The alignment length, number of matches and mismatches are 296, 280 and 16, respectively. Total number of matched nucleotides between query and germline <italic toggle="yes">IGHV</italic> sequence is used to calculate percent identity e.g., 100*(280/296) = 96.4%. N-junctional sequences are highlighted in gray boxes. (<bold>b</bold>) Fraction of the <italic toggle="yes">IGHV</italic> gene assembled in two CLL RNA-seq datasets with different sequence depths and lengths as indicated. An unpaired two-tailed <italic toggle="yes">t</italic>-test demonstrated no significant (<italic toggle="yes">P =</italic> 0.15) difference between the two distributions (NS). (<bold>c</bold>) Scatter plot comparing the percent of mutation of <italic toggle="yes">IGHV</italic> as predicted by CRIS and clinical PCR-Sanger-based analysis for 16 CLL patient samples obtained from GSE66228</p>
        </caption>
        <graphic xlink:href="vbab021f3" position="float"/>
      </fig>
      <table-wrap position="float" id="vbab021-T2">
        <label>Table 2.</label>
        <caption>
          <p>Concordance of <italic toggle="yes">IGHV</italic> gene prediction and percent mutation between PCR-Sanger-based analysis and CRIS</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="center" span="1"/>
            <col valign="top" align="center" span="1"/>
            <col valign="top" align="center" span="1"/>
            <col valign="top" align="center" span="1"/>
            <col valign="top" align="center" span="1"/>
            <col valign="top" align="center" span="1"/>
            <col valign="top" align="char" char="." span="1"/>
            <col valign="top" align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="2" colspan="1">Sample ID</th>
              <th colspan="2" rowspan="1">Sanger<hr/></th>
              <th colspan="6" rowspan="1">CRIS<hr/></th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1">IGHV</th>
              <th rowspan="1" colspan="1">Mutation (%)</th>
              <th rowspan="1" colspan="1">IGHV</th>
              <th rowspan="1" colspan="1"><italic toggle="yes">IGHV</italic> mutation (%)</th>
              <th rowspan="1" colspan="1">IGHD</th>
              <th rowspan="1" colspan="1">IGHJ</th>
              <th rowspan="1" colspan="1">No. of Ig transcript</th>
              <th rowspan="1" colspan="1">No. of clonotype</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">US-1422282</td>
              <td rowspan="1" colspan="1">V1-69</td>
              <td rowspan="1" colspan="1">0.4</td>
              <td rowspan="1" colspan="1">IGHV1-69*04</td>
              <td rowspan="1" colspan="1">0.3</td>
              <td rowspan="1" colspan="1">IGHD6-19*01</td>
              <td rowspan="1" colspan="1">IGHJ4*02</td>
              <td rowspan="1" colspan="1">7</td>
              <td rowspan="1" colspan="1">4</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422366</td>
              <td rowspan="1" colspan="1">V1-18</td>
              <td rowspan="1" colspan="1">0.34</td>
              <td rowspan="1" colspan="1">IGHV1-18*04</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">IGHD3-3*01</td>
              <td rowspan="1" colspan="1">IGHJ6*02</td>
              <td rowspan="1" colspan="1">21</td>
              <td rowspan="1" colspan="1">5</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422311</td>
              <td rowspan="1" colspan="1">V3-11</td>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">IGHV3-11*01</td>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">IGHD4-17*01</td>
              <td rowspan="1" colspan="1">IGHJ4*02</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">4</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422278</td>
              <td rowspan="1" colspan="1">V3-74</td>
              <td rowspan="1" colspan="1">5.4</td>
              <td rowspan="1" colspan="1">IGHV3-74*01</td>
              <td rowspan="1" colspan="1">5.4</td>
              <td rowspan="1" colspan="1">IGHD5-18*01</td>
              <td rowspan="1" colspan="1">IGHJ6*02</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">3</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422335</td>
              <td rowspan="1" colspan="1">V4-59</td>
              <td rowspan="1" colspan="1">10.2</td>
              <td rowspan="1" colspan="1">IGHV4-59*02</td>
              <td rowspan="1" colspan="1">8.5</td>
              <td rowspan="1" colspan="1">IGHD3-10*01</td>
              <td rowspan="1" colspan="1">IGHJ4*02</td>
              <td rowspan="1" colspan="1">3</td>
              <td rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422321</td>
              <td rowspan="1" colspan="1">V3-66</td>
              <td rowspan="1" colspan="1">0.7</td>
              <td rowspan="1" colspan="1">IGHV3-66*02</td>
              <td rowspan="1" colspan="1">0.7</td>
              <td rowspan="1" colspan="1">NA</td>
              <td rowspan="1" colspan="1">IGHJ4*02</td>
              <td rowspan="1" colspan="1">9</td>
              <td rowspan="1" colspan="1">4</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422333</td>
              <td rowspan="1" colspan="1">V4-34</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">IGHV4-34*01</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">IGHD3-3*01</td>
              <td rowspan="1" colspan="1">IGHJ6*02</td>
              <td rowspan="1" colspan="1">6</td>
              <td rowspan="1" colspan="1">3</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422356</td>
              <td rowspan="1" colspan="1">V2-70</td>
              <td rowspan="1" colspan="1">0.8</td>
              <td rowspan="1" colspan="1">IGHV2-70*01</td>
              <td rowspan="1" colspan="1">0.3</td>
              <td rowspan="1" colspan="1">IGHD3-16*01</td>
              <td rowspan="1" colspan="1">IGHJ3*02</td>
              <td rowspan="1" colspan="1">15</td>
              <td rowspan="1" colspan="1">8</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422368</td>
              <td rowspan="1" colspan="1">V3-74</td>
              <td rowspan="1" colspan="1">6.1</td>
              <td rowspan="1" colspan="1">IGHV3-74*03</td>
              <td rowspan="1" colspan="1">8.8</td>
              <td rowspan="1" colspan="1">IGHD1-1*01</td>
              <td rowspan="1" colspan="1">IGHJ5*02</td>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422309</td>
              <td rowspan="1" colspan="1">V3-53</td>
              <td rowspan="1" colspan="1">8.8</td>
              <td rowspan="1" colspan="1">IGHV3-53*01</td>
              <td rowspan="1" colspan="1">6.1</td>
              <td rowspan="1" colspan="1">IGHD3-10*01</td>
              <td rowspan="1" colspan="1">IGHJ6*03</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">3</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422302</td>
              <td rowspan="1" colspan="1">V2-70</td>
              <td rowspan="1" colspan="1">0.3</td>
              <td rowspan="1" colspan="1">IGHV2-70*01</td>
              <td rowspan="1" colspan="1">0.3</td>
              <td rowspan="1" colspan="1">IGHD2-15*01</td>
              <td rowspan="1" colspan="1">IGHJ4*02</td>
              <td rowspan="1" colspan="1">20</td>
              <td rowspan="1" colspan="1">4</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422351</td>
              <td rowspan="1" colspan="1">V1-46</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">IGHV1-46*01</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">IGHD3-10*01</td>
              <td rowspan="1" colspan="1">IGHJ4*02</td>
              <td rowspan="1" colspan="1">6</td>
              <td rowspan="1" colspan="1">3</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422314</td>
              <td rowspan="1" colspan="1">V1-3</td>
              <td rowspan="1" colspan="1">0.7</td>
              <td rowspan="1" colspan="1">IGHV1-3*01</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">IGHD6-19*01</td>
              <td rowspan="1" colspan="1">IGHJ4*02</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">3</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422342</td>
              <td rowspan="1" colspan="1">V3-21</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">IGHV3-21*01</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">IGHD3-16*01</td>
              <td rowspan="1" colspan="1">IGHJ4*02</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422350</td>
              <td rowspan="1" colspan="1">V3-48</td>
              <td rowspan="1" colspan="1">2.8</td>
              <td rowspan="1" colspan="1">IGHV3-48*03</td>
              <td rowspan="1" colspan="1">2.4</td>
              <td rowspan="1" colspan="1">IGHD3-22*01</td>
              <td rowspan="1" colspan="1">IGHJ4*02</td>
              <td rowspan="1" colspan="1">3</td>
              <td rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">US-1422352</td>
              <td rowspan="1" colspan="1">V1-46</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">IGHV1-46*01</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">IGHD3-22*01</td>
              <td rowspan="1" colspan="1">IGHJ6*02</td>
              <td rowspan="1" colspan="1">17</td>
              <td rowspan="1" colspan="1">4</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="tblfn1">
            <p><italic toggle="yes">Notes</italic>: CRIS reconstructed <italic toggle="yes">V-D-J</italic> segments of Ig transcripts and identified multiple transcripts per sample that belong to different clonotypes. NA is used in cases where <italic toggle="yes">IGHD</italic> genes were absent.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Having established that enrichment of sequences using our Ig feature set significantly reduced compute resources without a reduction in the sensitivity, we next examined the impact of RNA-seq sequencing depth. For this, we leveraged a set of 16 CLL RNA-seq libraries with an average of ∼28 million paired reads from GSE66228 (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic>, 2015</xref>) and compared these to the results obtained from our deeply sequenced CEMT libraries (∼300 million paired reads). We found no significant difference in the fraction of the <italic toggle="yes">IGHV</italic> gene assembled between deep and shallow RNA-seq libraries (<xref rid="vbab021-F3" ref-type="fig">Fig. 3b</xref>). This appears to be in part due to the high expression level of the dominating clone in the GSE66228 dataset (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic>, 2015</xref>) driving sufficient sequence read coverage (at least 10<sup>4</sup> reads) for Trinity to assemble the Ig transcript. However, as expected, the overall number of Ig transcripts identified correlated with the sequencing depth. Based on this analysis, we developed a pipeline called CRIS and benchmarked its ability to call <italic toggle="yes">IGHV</italic> mutation status. In the CRIS pipeline, we automate the process of read extraction from our novel putative Ig coordinates, perform quality trimming of selected sequence reads, assemble transcripts, enumerate transcript abundances and identify somatic mutations using reference germline sequences for SHM classification.</p>
    </sec>
    <sec>
      <title>3.3 CRIS is concordant with clinical <italic toggle="yes">IGHV</italic> mutation status</title>
      <p>Having established that CRIS could efficiently assembly <italic toggle="yes">IGHV</italic> transcripts, we explored its ability to call SHM mutation status in CLL. Unmutated CLL (uCLL) is clinically defined by <italic toggle="yes">IGHV</italic> sequence alignments of &gt;98% identity to the reference sequence (<xref rid="vbab021-B12" ref-type="bibr">Georgiou <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="vbab021-B24" ref-type="bibr">Monk <italic toggle="yes">et al.</italic>, 2017</xref>). To benchmark CRIS against gold standard Sanger-based clinical classification, we analyzed a series of published RNA-seq libraries from CLL patients with matched Sanger sequencing classifications. CRIS reported SHM on clonally amplified Ig transcripts and its classification of mutated/unmutated CLL (mCLL/uCLL) showed perfect concordance with Sanger-based clinical calls in the GSE66228 dataset (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic>, 2015</xref>; <xref rid="vbab021-T2" ref-type="table">Table 2</xref>). The percent mutations reported by CRIS and the clinical test were also highly correlated (Pearson’s <italic toggle="yes">r</italic> = 0.95, 95% CI 0.86–0.98; <xref rid="vbab021-F3" ref-type="fig">Fig. 3c</xref>). The reported <italic toggle="yes">IGHV</italic> mutational frequency was identical in 8/16 cases with the remaining cases showing small deviations (mean deviation 0.22%) that did not change the SHM classification. In seven of the eight divergent cases, the percent <italic toggle="yes">IGHV</italic> identity reported by the Sanger-based test was higher compared to CRIS (<xref rid="vbab021-T2" ref-type="table">Table 2</xref>). Closer inspection of the alignments revealed that this likely an artifact in the Sanger calls due to incomplete <italic toggle="yes">IGHV</italic> coverage by the PCR product used as denominator to calculate percent identity (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic>, 2015</xref>). In addition to calling mCLL/uCLL status, CRIS also reported 2–8 dominant clonotypes in the GSE66228 dataset, a feature not detected by clinical Sanger-based classifiers.</p>
      <p>We further benchmarked CRIS using two independent CLL RNA-seq datasets with matched <italic toggle="yes">IGHV</italic> mutation status determined by Sanger sequencing. In the phs000435.v3 dataset (<xref rid="vbab021-B32" ref-type="bibr">Wang <italic toggle="yes">et al.</italic>, 2011</xref>), CRIS calls were identical to the Sanger-based calls in 50/51 cases with 98.3% accuracy, 100% sensitivity and 97.3% specificity (<xref rid="vbab021-F4" ref-type="fig">Fig. 4a</xref>). A single sample (DFCI-5121) was reported as mCLL (<xref rid="vbab021-B32" ref-type="bibr">Wang <italic toggle="yes">et al.</italic>, 2011</xref>), however, CRIS determined it as uCLL. In the third independent dataset, EGAD00001004046 (<xref rid="vbab021-B3" ref-type="bibr">Beekman <italic toggle="yes">et al.</italic>, 2018</xref>), CRIS agreed with clinical classification in all cases and determined the identical <italic toggle="yes">IGHV</italic> gene as the dominant clone (<xref rid="vbab021-F4" ref-type="fig">Fig. 4b</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1b</xref>).</p>
      <fig position="float" id="vbab021-F4">
        <label>Fig. 4.</label>
        <caption>
          <p>Comparison of CRIS with clinical data and existing tools. (<bold>a and b</bold>) Confusion matrix represents the classification accuracy of CRIS compared to Sanger-PCR data in two independent CLL cohorts. The <italic toggle="yes">P</italic>-value was calculated by one-sided binomial test. (<bold>c</bold>) Comparison of CRIS, V’DJer and TRUST to reconstruct the proportion of <italic toggle="yes">IGHV</italic> sequences in GSE66228 (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic>, 2015</xref>) dataset. The average fraction of IGHV gene length for each tool is represented by dashed horizontal lines</p>
        </caption>
        <graphic xlink:href="vbab021f4" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>3.4 Comparison of CRIS against existing tools</title>
      <p>We next compared CRIS with previously published tools: V’DJer (<xref rid="vbab021-B25" ref-type="bibr">Mose <italic toggle="yes">et al.</italic>2016</xref>), TRUST (<xref rid="vbab021-B17" ref-type="bibr">Hu <italic toggle="yes">et al.</italic>, 2019</xref>) and MiXCR (<xref rid="vbab021-B6" ref-type="bibr">Bolotin <italic toggle="yes">et al.</italic>, 2015</xref>) that reconstruct BCR repertoires from short-read RNA-seq data. In 16 CLL RNA-seq samples obtained from GSE66228 (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic>, 2015</xref>), V’DJer did not produce full-length <italic toggle="yes">IGHV</italic> as it is designed to generate contigs of fixed length (360 bp) spanning the CDR3 region. Thus, on average, V’DJer assembled 75.44% of the <italic toggle="yes">IGHV</italic> gene whereas CRIS reconstructed 99.74% (<xref rid="vbab021-F4" ref-type="fig">Fig. 4c</xref>). Partial reconstruction of the <italic toggle="yes">IGHV</italic> gene could lead to misclassification of <italic toggle="yes">IGHV</italic> mutation status especially for samples with <italic toggle="yes">IGHV</italic> sequence identity near the established 98% cutoff. For example, CRIS reconstructed 295 bp out of 296 bp of the <italic toggle="yes">IGHV3-74*03</italic> sequence whereas V’DJer assembled 226 bp in US-1422368 (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S3a</xref> and b). The additional 69 bp reported by CRIS contained two mutations that resulted in a 1.2% difference in reported percent identity between CRIS (91.2%) and V’DJer (89.4%). TRUST assembled only 41.5% of the <italic toggle="yes">IGHV</italic> gene on average using the GSE66228 dataset (<xref rid="vbab021-F4" ref-type="fig">Fig. 4c</xref>). Furthermore, V’DJer and TRUST did not produce a contig for US-1422282 that contained <italic toggle="yes">IGHV1-69</italic> gene whereas CRIS generated <italic toggle="yes">IGHV1-69</italic> containing contig in agreement with the clinical call.</p>
      <p>To compare the computational performance between CRIS and V’DJer, both of the pipelines were configured to use up to 16 threads. In the shallow libraries from GSE66228 dataset, CRIS had ∼14% faster total run time (average 3.07 wall-clock minutes) compared to V’DJer (average 3.50 wall-clock minutes). Using deeper RNA-seq datasets (∼300 million reads) V’DJer took five times more time to run than CRIS (87 versus 16 wall-clock minutes on average). Using 16 threads, TRUST took 36 wall-clock minutes on average using GSE66228, an order of magnitude longer than CRIS. MiXCR (<xref rid="vbab021-B6" ref-type="bibr">Bolotin <italic toggle="yes">et al.</italic>, 2015</xref>) generated partial CDR3 sequence contigs with &lt;10% of <italic toggle="yes">IGHV</italic> gene sequence in the GSE66228 dataset of 75 bp read length. MiXCR recommends ≥100 bp read length to extract CDR3 repertoires from RNA-Seq data. Thus, our comparisons suggest that existing BCR reconstruction tools developed to extract just CDR3 regions perform poorly compared to CRIS in the determination of SHM status because they are designed to generate and analyze partial <italic toggle="yes">IGHV</italic> sequences. Overall, CRIS showed increased sensitivity and specificity and reduced run time over existing RNA-seq-based BCR reconstruction tools.</p>
    </sec>
  </sec>
  <sec>
    <title>4 Discussion</title>
    <p>PCR-Sanger-based Ig SHM classification is resource-intensive, subject to PCR bias, and suffers from an ∼9% to 18% failure rate (<xref rid="vbab021-B13" ref-type="bibr">Ghia <italic toggle="yes">et al.</italic>, 2007</xref>; <xref rid="vbab021-B30" ref-type="bibr">Stamatopoulos <italic toggle="yes">et al.</italic>, 2017</xref>). In contrast, RNA-seq is now routinely applied in the clinical setting, eliminates the need for targeted amplification of Ig locus and can be used to identify BCR rearrangement repertoire (<xref rid="vbab021-B5" ref-type="bibr">Blachly <italic toggle="yes">et al.</italic>, 2015</xref>). Here, we showed that CRIS can rapidly analyze RNA-seq to detect <italic toggle="yes">IGHV</italic> mutation status in CLL at a sensitivity and specificity equivalent to current Sanger-based clinical tests. Furthermore, CRIS was able to reconstruct the entire <italic toggle="yes">IGHV</italic> sequence thus increasing the accuracy of SHM classification. This is in contrast to a majority of existing pipelines designed to infer only CDR3-derived sequences (<xref rid="vbab021-B6" ref-type="bibr">Bolotin <italic toggle="yes">et al.</italic>, 2015</xref>; <xref rid="vbab021-B17" ref-type="bibr">Hu <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="vbab021-B25" ref-type="bibr">Mose <italic toggle="yes">et al.</italic>2016</xref>).</p>
    <p>A registry of ∼1500 CLL patients showed that 90% of patients were not screened for <italic toggle="yes">IGHV</italic> mutations (<xref rid="vbab021-B22" ref-type="bibr">Mato <italic toggle="yes">et al.</italic>, 2016</xref>). In the public domain, there are thousands of RNA-seq data available for different B-cell malignancies but their SHM status of <italic toggle="yes">IGHV</italic> genes is either not reported or partially reported. Furthermore, for a majority of publicly available RNA-seq datasets where SHM status is reported, detailed <italic toggle="yes">IGHV</italic> mutation reports with gene name, percent identity and clonal frequency are not available restricting the ability to assess mutational values. To meet this need, we developed CRIS and demonstrated its ability to rapidly classify <italic toggle="yes">IGVH</italic> mutational status with clinical accuracy. We anticipate that CRIS will prove to be useful in the mining of available B-cell RNA-seq datasets and that it will provide a framework to incorporate RNA-seq as a diagnostic tool to examine the BCR clonal rearrangement and SHM status.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>vbab021_Supplementary_Data</label>
      <media xlink:href="vbab021_supplementary_data.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>The authors wish to acknowledge Canada’s Michael Smith Genome Sciences Centre, Vancouver, BC Canada for computational resources and support. The results published here are in part based upon data generated by the Canadian Epigenetics, Epigenomics, Environment and Health Research Consortium (CEEHRC) initiative funded by the Canadian Institutes of Health Research (CIHR), Genome BC and Genome Quebec. Information about CEEHRC and the participating investigators and institutions can be found at <ext-link xlink:href="http://www.cihr-irsc.gc.ca/e/43734.html" ext-link-type="uri">http://www.cihr-irsc.gc.ca/e/43734.html</ext-link>. This study makes use of data (EGAD00001004046) generated by the Blueprint Consortium. A full list of the investigators who contributed to the generation of the data is available from <ext-link xlink:href="http://www.blueprint-epigenome.eu" ext-link-type="uri">www.blueprint-epigenome.eu</ext-link>. Funding for the project was provided by the European Union’s Seventh Framework Program [FP7/2007-2013] under grant agreement no 282510—BLUEPRINT. This study makes use of phs000435.v3 from NIH dbGaP, which was supported by the National Human Genome Research Institute [5U54HG003067], the Blavatnik Family Foundation, NCI (5R21CA115043-2), the Howard Hughes Medical Institute and the Damon-Runyon Cancer Research Foundation [CI-38-07].</p>
    <sec>
      <title>Funding</title>
      <p>This work was supported by the Canadian Institutes of Health Research (EP1-120589 and CEE-151619) and Genome Canada (C41EMT and C32EMT) under the Canadian Epigenetics, Environment and Health Research Consortium (to M.H.) and by the Terry Fox Research Institute Program Projects [TFF‐122869 and TFRI-1074] awarded to M.H. R.I. was supported by CIHR Bioinformatics Training Program for Health Research, University of British Columbia, Vancouver, BC, Canada.</p>
    </sec>
    <sec sec-type="data-availability">
      <title>Data availability</title>
      <p>The sequencing data reported in this study is accessible through the European Genome-Phenome Archive (EGA) under accession number EGAS00001000552.</p>
      <p><italic toggle="yes">Conflict of Interest</italic>: none declared.</p>
    </sec>
  </ack>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="vbab021-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akkaya</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>B cell memory: building two walls of protection against pathogens</article-title>. <source>Nat. Rev. Immunol</source>., <volume>20</volume>, <fpage>229</fpage>–<lpage>238</lpage>.<pub-id pub-id-type="pmid">31836872</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Altschul</surname><given-names>S.F.</given-names></string-name></person-group><etal>et al</etal> (<year>1990</year>) <article-title>Basic local alignment search tool</article-title>. <source>J. Mol. Biol</source>., <volume>215</volume>, <fpage>403</fpage>–<lpage>410</lpage>.<pub-id pub-id-type="pmid">2231712</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beekman</surname><given-names>R.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia</article-title>. <source>Nat. Med</source>., <volume>24</volume>, <fpage>868</fpage>–<lpage>880</lpage>.<pub-id pub-id-type="pmid">29785028</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berget</surname><given-names>E.</given-names></string-name></person-group><etal>et al</etal> (<year>2015</year>) <article-title>IGHV gene usage and mutational status in follicular lymphoma: correlations with prognosis and patient age</article-title>. <source>Leuk. Res</source>., <volume>39</volume>, <fpage>702</fpage>–<lpage>708</lpage>.<pub-id pub-id-type="pmid">25900812</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blachly</surname><given-names>J.S.</given-names></string-name></person-group><etal>et al</etal> (<year>2015</year>) <article-title>Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>, <volume>112</volume>, <fpage>4322</fpage>–<lpage>4327</lpage>.<pub-id pub-id-type="pmid">25787252</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bolotin</surname><given-names>D.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2015</year>) <article-title>MiXCR: software for comprehensive adaptive immunity profiling</article-title>. <source>Nat. Methods</source>, <volume>12</volume>, <fpage>380</fpage>–<lpage>381</lpage>.<pub-id pub-id-type="pmid">25924071</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyd</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Joshi</surname><given-names>S.A.</given-names></string-name></person-group> (<year>2014</year>) <article-title>High-throughput DNA sequencing analysis of antibody repertoires</article-title>. <source>Microbiol. Spectr</source>., <volume>2, 5 2.5.23</volume>.</mixed-citation>
    </ref>
    <ref id="vbab021-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Briney</surname><given-names>B.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Commonality despite exceptional diversity in the baseline human antibody repertoire</article-title>. <source>Nature</source>, <volume>566</volume>, <fpage>393</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">30664748</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B9">
      <mixed-citation publication-type="other"><collab>Broad Institute</collab>. (<year>2009</year>) Picard tools—by Broad Institute. <ext-link xlink:href="http://broadinstitute.github.io/picard" ext-link-type="uri">http://broadinstitute.github.io/picard</ext-link>.</mixed-citation>
    </ref>
    <ref id="vbab021-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Damle</surname><given-names>R.N.</given-names></string-name></person-group><etal>et al</etal> (<year>1999</year>) <article-title>Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia</article-title>. <source>Blood</source>, <volume>94</volume>, <fpage>1840</fpage>–<lpage>1847</lpage>.<pub-id pub-id-type="pmid">10477712</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dobin</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2013</year>) <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source>, <volume>29</volume>, <fpage>15</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">23104886</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Georgiou</surname><given-names>G.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) <article-title>The promise and challenge of high-throughput sequencing of the antibody repertoire</article-title>. <source>Nat. Biotechnol</source>., <volume>32</volume>, <fpage>158</fpage>–<lpage>168</lpage>.<pub-id pub-id-type="pmid">24441474</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghia</surname><given-names>P.</given-names></string-name></person-group><etal>et al</etal>; <collab>European Research Initiative on CLL</collab>. (<year>2007</year>) <article-title>ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia</article-title>. <source>Leukemia</source>, <volume>21</volume>, <fpage>1</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">17167526</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B29">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Giudicelli</surname><given-names>V.</given-names></string-name></person-group><etal>et al</etal> (<year>2005</year>) IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. <italic toggle="yes">Nucleic Acids Res.</italic>, 33, D256–D261.</mixed-citation>
    </ref>
    <ref id="vbab021-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grabherr</surname><given-names>M.G.</given-names></string-name></person-group><etal>et al</etal> (<year>2011</year>) <article-title>Full-length transcriptome assembly from RNA-Seq data without a reference genome</article-title>. <source>Nat. Biotechnol</source>., <volume>29</volume>, <fpage>644</fpage>–<lpage>652</lpage>.<pub-id pub-id-type="pmid">21572440</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hamblin</surname><given-names>T.J.</given-names></string-name></person-group><etal>et al</etal> (<year>1999</year>) <article-title>Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia</article-title>. <source>Blood</source>, <volume>94</volume>, <fpage>1848</fpage>–<lpage>1854</lpage>.<pub-id pub-id-type="pmid">10477713</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hölzer</surname><given-names>M.</given-names></string-name>, <string-name><surname>Marz</surname><given-names>M.</given-names></string-name></person-group> (<year>2019</year>) <article-title>De novo transcriptome assembly: a comprehensive cross-species comparison of short-read RNA-Seq assemblers</article-title>. <source>Gigascience</source>, <volume>8</volume>, <fpage>1</fpage>–<lpage>16</lpage>.</mixed-citation>
    </ref>
    <ref id="vbab021-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname><given-names>X.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Landscape of B cell immunity and related immune evasion in human cancers</article-title>. <source>Nat. Genet</source>., <volume>51</volume>, <fpage>560</fpage>–<lpage>567</lpage>.<pub-id pub-id-type="pmid">30742113</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iglesia</surname><given-names>M.D.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) <article-title>Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer</article-title>. <source>Clin. Cancer Res</source>., <volume>20</volume>, <fpage>3818</fpage>–<lpage>3829</lpage>.<pub-id pub-id-type="pmid">24916698</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B19">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Janeway</surname><given-names>C.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2004</year>) Janeway's Immunobiology. New York: Garland Science.</mixed-citation>
    </ref>
    <ref id="vbab021-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H.</given-names></string-name>, <string-name><surname>Durbin</surname><given-names>R.</given-names></string-name></person-group> (<year>2009</year>) <article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title>. <source>Bioinformatics</source>, <volume>25</volume>, <fpage>1754</fpage>–<lpage>1760</lpage>.<pub-id pub-id-type="pmid">19451168</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mandric</surname><given-names>I.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>Profiling immunoglobulin repertoires across multiple human tissues using RNA sequencing</article-title>. <source>Nat. Commun</source>., <volume>11</volume>, <fpage>1</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">31911652</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mato</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) <article-title>Real-world clinical experience in the Connect<sup>®</sup> chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres</article-title>. <source>Br. J. Haematol</source>., <volume>175</volume>, <fpage>892</fpage>–<lpage>903</lpage>.<pub-id pub-id-type="pmid">27861736</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Menzel</surname><given-names>U.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) <article-title>Comprehensive evaluation and optimization of amplicon library preparation methods for high-throughput antibody sequencing</article-title>. <source>PLoS One</source>, <volume>9</volume>, <fpage>e96727</fpage>.<pub-id pub-id-type="pmid">24809667</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Monk</surname><given-names>J.M.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>Antigen receptor repertoire profiling from RNA-seq data</article-title>. <source>Nat. Biotechnol</source>., <volume>35</volume>, <fpage>908</fpage>–<lpage>911</lpage>.<pub-id pub-id-type="pmid">29020005</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mose</surname><given-names>L.E.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V’DJer. <italic toggle="yes">Bioinformatics</italic>, <volume>32</volume>, <fpage>3729</fpage>–<lpage>3734</lpage>.</mixed-citation>
    </ref>
    <ref id="vbab021-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Navarro</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2012</year>) <article-title>Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features</article-title>. <source>Cancer Res</source>., <volume>72</volume>, <fpage>5307</fpage>–<lpage>5316</lpage>.<pub-id pub-id-type="pmid">22915760</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patro</surname><given-names>R.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title>. <source>Nat. Methods</source>, <volume>14</volume>, <fpage>417</fpage>–<lpage>419</lpage>.<pub-id pub-id-type="pmid">28263959</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pellacani</surname><given-names>D.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) <article-title>Analysis of normal human mammary epigenomes reveals cell-specific active enhancer states and associated transcription factor networks</article-title>. <source>Cell Rep</source>., <volume>17</volume>, <fpage>2060</fpage>–<lpage>2074</lpage>.<pub-id pub-id-type="pmid">27851968</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stamatopoulos</surname><given-names>B.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia</article-title>. <source>Leukemia</source>, <volume>31</volume>, <fpage>837</fpage>–<lpage>845</lpage>.<pub-id pub-id-type="pmid">27795555</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tarasov</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2015</year>) <article-title>Sambamba: fast processing of NGS alignment formats</article-title>. <source>Bioinformatics</source>, <volume>31</volume>, <fpage>2032</fpage>–<lpage>2034</lpage>.<pub-id pub-id-type="pmid">25697820</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>L.</given-names></string-name></person-group><etal>et al</etal> (<year>2011</year>) <article-title>SF3B1 and other novel cancer genes in chronic lymphocytic leukemia</article-title>. <source>N. Engl. J. Med</source>., <volume>365</volume>, <fpage>2497</fpage>–<lpage>2506</lpage>.<pub-id pub-id-type="pmid">22150006</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yaari</surname><given-names>G.</given-names></string-name>, <string-name><surname>Kleinstein</surname><given-names>S.H.</given-names></string-name></person-group> (<year>2015</year>) <article-title>Practical guidelines for B-cell receptor repertoire sequencing analysis</article-title>. <source>Genome Med</source>., <volume>7</volume>, <fpage>121</fpage>.<pub-id pub-id-type="pmid">26589402</pub-id></mixed-citation>
    </ref>
    <ref id="vbab021-B34">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Ye</surname><given-names>J.</given-names></string-name></person-group><etal>et al</etal>. (<year>2013</year>) <article-title>IgBLAST: an immunoglobulin variable domain sequence analysis tool</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>41</volume>, <fpage>W34</fpage>–<publisher-loc>W40</publisher-loc>.<pub-id pub-id-type="pmid">23671333</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
